Charles River Labs stock gains as rapid cell banking push meets upbeat analyst targets

Published on 09/17/2026 at 21:43 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Charles River Labs stock trades near its 52-week high as of September 17, 2026, supported by new rapid cell banking programs and a Strong Buy analyst consensus. Recent price targets around USD 282 to USD 320 highlight modest upside from current levels.

CRL, US1598641074, Illustration mit AI erstellt.

Charles River Laboratories International, Inc. stock (ISIN US1598641074) is trading close to its recent highs around USD 283.94 on the NYSE as of September 17, 2026, with an intraday gain of 3.85 percent that keeps the valuation under scrutiny for investors.

Rapid cell banking initiative sets the tone

According to Business Wire on September 17, 2026, Charles River Laboratories has introduced rapid cell banking programs designed to significantly accelerate release timelines for biopharmaceutical and advanced therapy developers.

The company aims to shorten drug development timelines by integrating rapid cell bank and release services with advanced characterization technologies such as next-generation sequencing, positioning the offering as a way for clients to reach key milestones faster and potentially bring innovative treatments to patients sooner, as outlined in the release from the Wilmington based group.

Valuation, profitability and recent pricing

As of midday on September 17, 2026, data from a stock analytics portal show Charles River Laboratories stock quoted at about USD 283.94 on the NYSE, up USD 10.53 or 3.85 percent intraday at 12:11 p.m. Eastern Time, illustrating that the shares are still adding to the prior closing level near USD 273.41 observed on September 16, 2026.

Per a valuation focused analysis published on September 17, 2026, Charles River Laboratories recently closed at USD 273.41 with a price to sales ratio of 3.38, notably above an historical median near 2.8 times, and carries a trailing twelve month earnings per share of negative USD 4.85 alongside negative net margins, highlighting that the group is currently unprofitable even as the market prices in future growth expectations, according to GuruFocus.

The same analysis calculates a proprietary GF Value of USD 194.22 for Charles River Laboratories, around 40.8 percent below the spot market price level of USD 273.41 as of the close on September 16, 2026, underscoring the view that the stock appears significantly overvalued on that metric even though investors may be focusing on revenue growth potential and operational improvements.

Analyst consensus points to limited upside

Analyst coverage still leans constructive despite the rich valuation metrics. As The Globe and Mail reported on September 17, 2026, RBC Capital analyst Ryan Halsted maintained a Buy rating on Charles River Labs and set a price target of USD 282.00, referencing a recent closing level of USD 272.88 that stood very close to a 52-week high of USD 273.32.

The same overview cites an analyst consensus rating of Strong Buy for Charles River Labs, with a mean price target of USD 286.45 implying roughly 5.2 percent upside from the referenced current level, while highlighting that Evercore ISI has also reiterated a Buy stance with a higher price target of USD 320.00 in a report dated September 11, 2026, which together frame the market narrative of moderate further potential rather than a deep value story.

In parallel, a broader analyst and portal snapshot on September 17, 2026 shows an average price target around USD 282.43 and confirms that the latest closing price of USD 273.41 leaves only about a low single digit percentage gap to that average objective, according to Zonebourse.

Market action and risk perspective

The relatively tight spread between the prevailing market price near USD 273 to USD 284 and consensus targets clustered around the low USD 280s means that, on current numbers, the stock offers only a modest upside cushion versus typical analyst expectations, which can make the shares more sensitive to any disappointment in execution or in the uptake of new offerings such as the rapid cell banking programs.

From a risk viewpoint, the combination of a negative trailing twelve month earnings profile and a price to sales ratio elevated above historical norms suggests that investors are heavily weighting anticipated future revenue and margin improvements; for retail investors, that implies that any delay in converting pipeline opportunities into profitable growth could weigh disproportionately on the share price given the current valuation premium described by GuruFocus.

Stock level and investor takeaway

As of September 17, 2026, Charles River Laboratories stock around USD 283.94 on the NYSE, following a prior close of USD 273.41, trades near its 52-week high band and only a few percent below the average analyst price target, leaving a narrow buffer for upside while the company works to translate its rapid cell banking initiatives and broader service portfolio into sustained profitable growth.